Bioequivalence of Conjugated Estrogen Products

  title={Bioequivalence of Conjugated Estrogen Products},
  author={Rudi Ansbacher},
  journal={Clinical Pharmacokinetics},

Topics from this paper

Single dose pharmacokinetics and bioequivalence of conjugated estrogens (0.625 mg × 2) tablets in healthy post-menopausal female subjects in fasting and fed studies
Abstract Conjugated estrogens are sulfate esters of naturally occurring estrogens. The pharmacokinetics of various estrogen formulations is complex and varying due to its endogenous availability. TheExpand
Hormone Replacement Therapy
HRT is both medically and economically justified in women with severe menopausal symptoms, whereas compliance is an important factor in determining economic benefit in Women with less severe symptoms. Expand
Hormone Replacement Therapy
HRT appears to be most economically useful in the prevention of fracture if used in women who have undergone hysterectomy, in women with high risk of osteoporotic fracture or ischaemic heart disease, and/or inWomen with menopausal symptoms. Expand
Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
The objective of this review is to assess which hormone replacement therapy regimens provide effective protection against the development of endometrial hyperplasia and/or carcinoma with a low rate of abnormal vaginal bleeding. Expand
Bioequivalence criteria for cyclosporine.
Characterization of metabolites of Δ8,9-dehydroestrone in dogs
Δ8,9-Dehydroestrone is the fifth most abundant component in the conjugated equine estrogen preparation Premarin®, representing about 2 to 6% of the total steroids in the tablet. The metabolism ofExpand
Metabolism of equilin sulfate in the dog
The reduction of the 17-keto group and aromatization of ring-B are the major metabolic pathways of equilin in the dog and the radioactivity is rapidly absorbed following oral administration of [3H]equilin sulfate to dogs. Expand


Generic drugs: bioequivalence and bioavailability.
To the Editor. —In the SPECIAL COMMUNICATION by Nightingale and Morrison 1 concerning generic drugs, the subject of bioequivalence was discussed. However, no mention was made of bioavailability. InExpand
17 beta-estradiol for postmenopausal estrogen replacement therapy.
Efficacy of estrogens in the prevention of osteoporosis as assessed by densitometry has been demonstrated for conjugated oral estrogens, and efficacy of estrogen replacement for the treatment of the menopausal symptoms appears to relate to the magnitude of estradiol plasma levels. Expand